Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia

Schneider H, Hadj-Rabia S, Faschingbauer F, Bodemer C, Grange DK, Norton ME, Cavalli R, Tadini G, Stepan H, Clarke A, Guillén-Navarro E, Maier-Wohlfart S, Bouroubi A, Porte F (2023)

Publication Type: Journal article

Publication year: 2023

Journal

Genes Molecular Diversity Preservation International (MDPI)

Book Volume: 14

Article Number: 153

Journal Issue: 1

DOI: 10.3390/genes14010153

Abstract

X-linked hypohidrotic ectodermal dysplasia (XLHED) is a rare genetic disorder characte-rised by abnormal development of the skin and its appendages, such as hair and sweat glands, the teeth, and mucous glands of the airways, resulting in serious, sometimes life-threatening complications like hyperthermia or recurrent respiratory infections. It is caused by pathogenic variants of the ectodysplasin A gene (EDA). Most affected males are hemizygous for EDA null mutations that lead to the absence or inactivity of the signalling protein ectodysplasin A1 (EDA1) and, thus, to the full-blown phenotype with inability to perspire and few if any teeth. There are currently no long-term treatment options for XLHED. ER004 represents a first-in-class protein replacement molecule designed for specific, high-affinity binding to the endogenous EDA1 receptor (EDAR). Its proposed mechanism of action is the replacement of missing EDA1 in yet unborn patients with XLHED. Once bound to EDAR, ER004 activates the EDA/NFκB signalling pathway, which triggers the transcription of genes involved in the normal development of multiple tissues. Following preclinical studies, named-patient use cases demonstrated significant potential of ER004 in affected males treated in utero during the late second and third trimesters of pregnancy. In order to confirm these results, we started the EDELIFE trial, a prospective, open-label, genotype-match controlled, multicentre clinical study to investigate the efficacy and safety of intra-amniotic ER004 administration as a prenatal treatment for male subjects with XLHED. This article summarises the rationale, the study protocol, ethical issues of the trial, and potential pitfalls.

Authors with CRIS profile

Holm Schneider Professur für Kinderheilkunde/Experimentelle Perinatalmedizin Sigrun Maier-Wohlfart Department of Paediatrics and Adolescent Medicine

Involved external institutions

Hôpital Necker-Enfants malades FR France (FR) Pierre Fabre S.A FR France (FR) EspeRare CH Switzerland (CH) Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico IT Italy (IT) Washington University US United States (USA) (US) University of California San Francisco (UCSF) US United States (USA) (US) Hospital Clínico Universitario Virgen de la Arrixaca ES Spain (ES) Universitätsklinikum Leipzig DE Germany (DE) Cardiff University GB United Kingdom (GB)

How to cite

APA:

Schneider, H., Hadj-Rabia, S., Faschingbauer, F., Bodemer, C., Grange, D.K., Norton, M.E.,... Porte, F. (2023). Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia. Genes, 14(1). https://dx.doi.org/10.3390/genes14010153

MLA:

Schneider, Holm, et al. "Protocol for the Phase 2 EDELIFE Trial Investigating the Efficacy and Safety of Intra-Amniotic ER004 Administration to Male Subjects with X-Linked Hypohidrotic Ectodermal Dysplasia." Genes 14.1 (2023).

BibTeX: Download